Mixed
Anti-obesity medications (specifically GLP-1 agonists like Semaglutide and Liraglutide) facilitate significant weight loss in obese osteoarthritis (OA) patients, which reduces joint compressive forces and systemic inflammation, thereby alleviating pain and slowing structural progression.
For obese patients with knee OA, anti-obesity medications like Semaglutide (2.4 mg weekly) or Liraglutide (3.0 mg daily) are effective medical tools to achieve significant weight loss (up to 10-15% with other drugs, ~5-6kg with GLP-1s). This weight loss directly reduces the mechanical load on knees and lowers inflammatory markers, slowing OA progression. These drugs should be used as adjuncts to lifestyle changes, not replacements, and require long-term adherence as obesity is a chronic disease.
Weight loss may alleviate the symptoms of knee OA due to a reduction in joint compressive forces... Obesity causes an inflammatory synovial phenotype in the OA joint... Anti-obesity drugs contribute to as much as 15% weight loss in responders... Semaglutide... resulted in larger weight loss... compared with liraglutide.
Why this rating
Based on narrative review of multiple RCTs and meta-analyses, though direct long-term OA structural data for newer drugs is still emerging.
Source
A narrative review of anti-obesity medications for obese patients with osteoarthritis
Win Min Oo et al. · Expert Opinion on Pharmacotherapy · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →